Gensight Biologics SA
PAR:SIGHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gensight Biologics SA
PAR:SIGHT
|
FR |
|
Customers Bancorp Inc
NYSE:CUBI
|
US |
|
Kunshan Huguang Auto Harness Co Ltd
SSE:605333
|
CN |
|
C
|
China Boqi Environmental Holding Co Ltd
HKEX:2377
|
CN |
|
R
|
Rexit Bhd
KLSE:REXIT
|
MY |
|
Guoguang Electric Co Ltd
SZSE:002045
|
CN |
|
A
|
Accel Group Holdings Ltd
HKEX:1283
|
HK |
|
T
|
TPI Polene Power PCL
SET:TPIPP
|
TH |
|
V
|
Vinyl Group Ltd
ASX:VNL
|
AU |
|
Tongding Interconnection Information Co Ltd
SZSE:002491
|
CN |
|
K
|
KCP Sugar and Industries Corp Ltd
NSE:KCPSUGIND
|
IN |
|
F
|
Far Eastern University Inc
XPHS:FEU
|
PH |
|
Magontec Ltd
ASX:MGL
|
AU |
|
W
|
Wilton Resources Corporation Ltd
SGX:5F7
|
SG |
|
R
|
RPCG PCL
SET:RPC
|
TH |
Gensight Biologics SA
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
